Method for protecting humans against superficial vasodilator flush syndrome
View Patent ↗Methods for protection of a human from SVFS comprise the administration of a flavonoid compound of the basic structures 2-phenyl-4H-1-benzopyran or 2-phenyl-4-keto-1-benzopyran or glycosides thereof, alone or, optionally, together with one or more of an olive kernel extract, a non-bovine sulfated proteoglycan, bitter willow extract, a D-hexosamine sulfate, S-adenosylmethionine, folic acid, vitamin B12 and a serotonin inhibitor. Such treatment prevents, reduces or eliminates SVFS in patients receiving as much as 300-3000 mg/day of niacin therapeutically, whether administered prior to, or along with, an anti-SVFS composition.
1. A method for treating niacin-induced flush comprising administering to a patient in need thereof, a composition comprising an effective dose of a flavonoid compound, a non-bovine sulfated proteoglycan and olive kernel oil, wherein said flavonoid is selected from quercetin and luteolin.
2. The method of claim 1 wherein the method further comprises administration of cyproheptadine, prochlorperazine or azatadine.
3. The method of claim 1 additionally comprising administration of 300-3,000 mg of niacin.
4. The method of claim 3 , wherein said niacin is in a form selected from the group consisting of an immediate release form, a slow release form, an extended release form and a sustained release form.
5. The method of claim 4 , whereby said niacin is administered with an additional composition that lowers total serum cholesterol or lowers LDL cholesterol.
6. The method of claim 5 , wherein said additional composition that lowers total serum cholesterol or lowers LDL cholesterol is a statin.
7. The method of claim 6 , wherein said statin is selected from the group consisting of simvastatin, l-lovastatin, atorvastatin, rosuvastatin, fluvastatin and pravastatin.
8. The method of claim 3 , wherein the niacin is an extended release niacin.
9. The method of claim 3 , wherein said niacin is formulated with a prostaglandin D2 blocker.
10. The method of claim 9 , wherein said blocker is selected from the group consisting of cyclooxygenase inhibitors and prostaglandin D2 receptor antagonists.